Neuraminidase inhibitors for critically ill children with influenza
- PMID: 24276847
- PMCID: PMC6637754
- DOI: 10.1542/peds.2013-2149
Neuraminidase inhibitors for critically ill children with influenza
Abstract
Objective: Timely treatment with neuraminidase inhibitor (NAI) drugs appears to improve survival in adults hospitalized with influenza. We analyzed California surveillance data to determine whether NAI treatment improves survival in critically ill children with influenza.
Methods: We analyzed data abstracted from medical records to characterize the outcomes of patients aged 0 to 17 years hospitalized in ICUs with laboratory-confirmed influenza from April 3, 2009, through September 30, 2012.
Results: Seven hundred eighty-four influenza cases aged <18 years hospitalized in ICUs had information on treatment. Ninety percent (532 of 591) of cases during the 2009 H1N1 pandemic (April 3, 2009-August 31, 2010) received NAI treatment compared with 63% (121 of 193) of cases in the postpandemic period (September 1, 2010-September 30, 2012; P < .0001). Of 653 cases NAI-treated, 38 (6%) died compared with 11 (8%) of 131 untreated cases (odds ratio = 0.67, 95% confidence interval: 0.34-1.36). In a multivariate model that included receipt of mechanical ventilation and other factors associated with disease severity, the estimated risk of death was reduced in NAI-treated cases (odds ratio 0.36, 95% confidence interval: 0.16-0.83). Treatment within 48 hours of illness onset was significantly associated with survival (P = .04). Cases with NAI treatment initiated earlier in illness were less likely to die.
Conclusions: Prompt treatment with NAIs may improve survival of children critically ill with influenza. Recent decreased frequency of NAI treatment of influenza may be placing untreated critically ill children at an increased risk of death.
Keywords: antiviral; children; critically ill; influenza; mortality; neuraminidase inhibitor; pediatric; pediatric ICU.
Conflict of interest statement
Figures
Similar articles
-
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.J Infect Chemother. 2012 Dec;18(6):858-64. doi: 10.1007/s10156-012-0428-1. Epub 2012 May 29. J Infect Chemother. 2012. PMID: 22644080 Clinical Trial.
-
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.J Infect Chemother. 2018 Jun;24(6):449-457. doi: 10.1016/j.jiac.2018.01.013. Epub 2018 Feb 24. J Infect Chemother. 2018. PMID: 29487035
-
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.Antivir Ther. 2015;20(1):49-55. doi: 10.3851/IMP2798. Epub 2014 May 16. Antivir Ther. 2015. PMID: 24832015
-
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19. Lancet Respir Med. 2014. PMID: 24815805 Free PMC article. Review.
-
Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: summary of an ecological study.Influenza Other Respir Viruses. 2013 Sep;7 Suppl 2(Suppl 2):82-86. doi: 10.1111/irv.12092. Influenza Other Respir Viruses. 2013. PMID: 24034490 Free PMC article. Review.
Cited by
-
Influenza in Children and Adolescents: Epidemiology, Management, and Prevention.Pediatr Rev. 2023 Nov 1;44(11):605-617. doi: 10.1542/pir.2023-005962. Pediatr Rev. 2023. PMID: 37907421 Free PMC article.
-
Assessment of Temporal Patterns and Patient Factors Associated With Oseltamivir Administration in Children Hospitalized With Influenza, 2007-2020.JAMA Netw Open. 2022 Sep 1;5(9):e2233027. doi: 10.1001/jamanetworkopen.2022.33027. JAMA Netw Open. 2022. PMID: 36149655 Free PMC article.
-
Vital sign predictors of severe influenza among children in an emergent care setting.PLoS One. 2022 Aug 12;17(8):e0272029. doi: 10.1371/journal.pone.0272029. eCollection 2022. PLoS One. 2022. PMID: 35960719 Free PMC article.
-
Guideline-Concordant Antiviral Treatment in Children at High Risk for Influenza Complications.Clin Infect Dis. 2023 Feb 8;76(3):e1040-e1046. doi: 10.1093/cid/ciac606. Clin Infect Dis. 2023. PMID: 35867691 Free PMC article.
-
Useful clinical findings and simple laboratory data for the diagnosis of seasonal influenza.J Gen Fam Med. 2021 Feb 28;22(5):231-236. doi: 10.1002/jgf2.431. eCollection 2021 Sep. J Gen Fam Med. 2021. PMID: 34484991 Free PMC article.
References
-
- Louie JK, Acosta M, Winter K, et al.; California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896–1902 - PubMed
-
- Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708–1719 - PubMed
-
- Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children—Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep. 2009;58(15):400–402 - PubMed
-
- Garg S, Fry AM, Patton M, Fiore AE, Finelli L. Antiviral treatment of influenza in children. Pediatr Infect Dis J. 2012;31(2):e43–e51 - PubMed
-
- Louie JK, Gavali S, Acosta M, et al.; California Pandemic (H1N1) Working Group. Children hospitalized with 2009 novel influenza A (H1N1) in California. Arch Pediatr Adolesc Med. 2010;164(11):1023–1031 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
